T. Rowe Price Associates
NMTR

T. Rowe Price Associates’s 9 Meters Biopharma NMTR Stock Holding History

T. Rowe Price Associates’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,081
Closed -$6K – 3065
2022
Q2 		$6K Buy
1,081
+91
+9% +$857 ﹤0.01% 2947
2022
Q1 		$12K Buy
990
+274
+38% +$3.74K ﹤0.01% 2962
2021
Q4 		$14K Sell
716
-275
-28% -$6.15K ﹤0.01% 2967
2021
Q3 		$26K Buy
991
+75
+8% +$1.77K ﹤0.01% 2929
2021
Q2 		$20K Buy
+916
New +$22.5K ﹤0.01% 2915

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
ODFS
O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

T. Rowe Price Associates's NMTR Position: Q3 2022 in Review

T. Rowe Price Associates sold out of 9 Meters Biopharma (NMTR) in Q3 2022, closing a stake of 1,081 shares — an estimated $6K sold.

T. Rowe Price Associates first reported a position in NMTR in Q2 2021 and held it in 5 quarters. The position peaked at $26K in Q3 2021. 74 funds tracked by Wall St. Rank hold NMTR as of Q3 2022.

  • T. Rowe Price Associates reported no remaining 9 Meters Biopharma position as of Q3 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,081 9 Meters Biopharma shares in Q3 2022, an estimated $6K.
  • T. Rowe Price Associates first reported a position in 9 Meters Biopharma in Q2 2021 and held it in 5 quarters.
  • T. Rowe Price Associates's 9 Meters Biopharma position peaked at $26K in Q3 2021.
  • 74 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q3 2022.

Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.